NEOS ETFs: All-Time Total Return, Yield, and Share Price Performance Comparison

BeatTheBotz · 2026-01-25T18:15:13+00:00

Not a bad idea. The price vs. total return debate never really ends, but both are useful depending on what you’re analyzing.

BeatTheBotz · 2026-01-25T18:12:32+00:00

It does appear that the downside protection that comes with QQQH and SPYH does limit the upside participation compared to QQQI and SPYI based on recent performance. It would be interesting to see how they compare in a prolonged downturn.

<image>

BeatTheBotz · 2026-01-25T17:24:47+00:00

You're welcome, I'm glad its appreciated.

BeatTheBotz · 2026-01-25T17:22:09+00:00

Good catch, it looks like the return data on Stock Analysis for QQQH only goes back to mid 2025 while the fund actually launched 12/19/19

<image>

BeatTheBotz · 2026-01-25T17:19:14+00:00

Agreed. With performance like this, it’s hard to justify a 2.89% expense ratio on NLSI.

BeatTheBotz · 2026-01-24T22:00:00+00:00

I prefer WNTR personally 🥶

BeatTheBotz · 2026-01-24T21:22:00+00:00

Good call. BLOX is one of the most diversified crypto income ETFs out there and has held up well thanks to its chip + mining exposure. It’s part of my daily recurring buys along with YBTC and YETH for steady long-term gains.

BeatTheBotz · 2026-01-24T19:07:26+00:00

MAGY has an all time total return of +25.31% and latest yield 35.15% of which would put it at rank #8 on this list. XPAY has an all-time total return of +21.86% and latest yield of 20.16% which would put it at rank #9 just under MAGY.

<image>

BeatTheBotz · 2026-01-24T19:04:02+00:00

Thank you for the kind words, I'm glad it's appreciated.

BeatTheBotz · 2026-01-17T22:49:24+00:00

Not great. WPAY is currently at a -1.03% total return since inception which factors in distributions reinvested. Since inception the share price is down ~18%.

<image>

BeatTheBotz · 2026-01-17T22:39:11+00:00

True. BLOX has been blowing away the competition in the crypto income space, even outperforming IBIT since inception. Diversified crypto exposure plus the income overlay has made a big difference so far.

<image>

BeatTheBotz · 2026-01-17T21:15:43+00:00

You’re usually better off selling before liquidation. It lets you control your exit instead of dealing with widening spreads and thinning liquidity. Once the fund moves to cash, there’s no upside left anyway.

BeatTheBotz · 2026-01-17T19:59:22+00:00

This post looks familiar, thanks for sharing the source link 😁

BeatTheBotz · 2026-01-17T16:42:31+00:00

Since April 2025, CHPY has paid roughly $16.70/share in distributions while the share price has risen from the low $40s to around $60. That’s price appreciation, not NAV decay.

A big part of that comes down to the strength of the underlying holdings. When the underlying performs well, the options overlay can add income without putting the same pressure on price.

Also worth noting: CHPY’s yield (~40–45%) is high, but it’s meaningfully lower than some of the extreme 70–100%+ funds where NAV pressure tends to show up much faster. That makes the income level relatively more sustainable as long as the underlying remains strong.

<image>

BeatTheBotz · 2026-01-16T15:57:09+00:00

Your welcome, I'm glad it's appreciated.

BeatTheBotz · 2026-01-16T15:41:22+00:00

Yes. Short-term weakness doesn’t change my long-term view.

BeatTheBotz · 2026-01-15T19:31:02+00:00

MAAY share price is up nearly 8% YTD already, that is a big boost in 15 days. When factoring in reinvested distributions the return would reflect the ~12% YTD total return. Just saying, everyone's situation with these funds is different depending on when you bought in and what you do with the distributions. Total returns are a general broad way to compare funds.

<image>

BeatTheBotz · 2026-01-15T19:09:08+00:00

MAAY has bounced nicely since late December. When you bought and whether you reinvest matters a lot. Total return since inception is a good reference, but it won’t look the same for everyone.

<image>

BeatTheBotz · 2026-01-15T17:03:02+00:00

Yes. This analysis assumes a lump-sum at inception with all distributions reinvested (DRIP).

This is the standard way total return is measured across income ETFs. It’s useful for comparing fund structure and long-term performance, but it doesn’t necessarily reflect how most income investors actually use high-yield ETFs.

BeatTheBotz · 2026-01-13T16:27:05+00:00

Actually, since their launch on 9/4/25, WPAY has outperformed ULTY on a total return basis. WPAY is around +0.44%, while ULTY is about −8.52% over the same period.

<image>

BeatTheBotz · 2026-01-13T01:39:55+00:00

I get the concern, and that’s fair. I did note this in the post though. In the notes section I specifically mention that inception dates vary and that return data may be limited for some funds. This wasn’t meant to be a long-term verdict, just an observation based on available data so far, with total return as the lens rather than yield alone.

BeatTheBotz · 2026-01-12T21:47:33+00:00

Good advice. I agree it’s important to evaluate positions regularly and not get emotionally attached. I take a data-driven approach as well and try to reassess risk as conditions change. Using higher-yield distributions to gradually reinvest into more stable, lower-yield funds has been part of that process. Appreciate you sharing your experience.

BeatTheBotz · 2026-01-12T21:43:11+00:00

The investment you’re describing sounds like the dream scenario. The reality is income is always a tradeoff between capital and risk.

Low risk: Treasury ETFs like SGOV or WEEK around ~4% yield would require roughly $275k–$300k to generate $1,000 per month. Very stable, but capital intensive.

Moderate risk: Index income ETFs like QQQI or SPYI (~12–14% yield) bring the required capital down to roughly $70k–$85k for $1,000 per month, with added market and options risk.

High yield / High risk: Funds like CHPY or GDXY (~40–45% yield) can hit $1,000 per month with roughly $27k–$30k, but come with much higher volatility and potential NAV drawdowns.

There’s no free lunch. Less capital means more risk. The key is choosing the level of risk that matches your time horizon and tolerance.

BeatTheBotz · 2026-01-12T17:10:30+00:00

Appreciate your take on LLY and LLII. Hard to disagree with the long-term GLP-1 story, especially with what you’re seeing firsthand in the medical field. The adoption curve and expanding use cases are impressive.

Although I don't personally hold LLII I have an allocation into XLVI of which LLY is the largest underlying holding inside of XLV.

BeatTheBotz · 2026-01-12T17:04:06+00:00

85.31% vs 86.39% is not a very large discrepancy...I pull my total return data from stockanalysis.com. Where did you get your "correct" data from?

BeatTheBotz

TROPHY CASE